PRRT2 and cancer: In summary, our analysis of cancer-associated mutations in PKCθ reveals two distinct mechanisms by which signaling output is impaired — either by enhancing autoinhibition or by disrupting autoinhibition to promote degradation and loss of protein (Figure 7).